Across TCGA pan-cancer cohorts, FAM126A Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FAM126A data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FAM126A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM126A expression acts as an unfavorable survival marker.
HNSC are the cancer types where FAM126A Mutation most reproducibly stratifies survival.